EP300 and skin basal cell carcinoma: Additionally, in the Ruijin cohort, TP53Mut patients had significantly increased mutations in EP300 and NOTCH2, but decreased mutations in SOCS1 and CD70. In the BCC cohort, TP53Mut patients had significantly decreased APF36L1 mutations.